get a key
steadybase-$ company NKTR
account_id none on file
legal_name Nektar Therapeutics
ticker NKTR
cik 906709
domain nektar.com
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
hq San Francisco, CA, United States
calls 0 filings 12 executives 2 family 0
why_nownone on file
callsnone on file
filings
b) Includes legal and patent expenses, information technology infrastructure and other costs, professional accounting, insurance, travel and entertainment and other third party services and expenses.

filing / Aug 14, 2026 / receipt

As discussed in Note 8 to our Condensed Consolidated Financial Statements, we have incurred significant contract termination costs as a result of our prior restructuring plans.

filing / Aug 14, 2026 / receipt

As a result of our prior restructuring plans, we are seeking to sublease all of our leased facilities in San Francisco, California, including our laboratory and office space on Mission Bay Blvd.

filing / Aug 14, 2026 / receipt

South (the Mission Bay Facility) and our office space on Third St. (the Third. St. Facility), and we have current subleases for a portion of the Mission Bay Facility.

filing / Aug 14, 2026 / receipt

In connection with our prior restructuring plans, we have incurred significant contract termination costs. We continue to recognize expense until settlement.

filing / Aug 14, 2026 / receipt

Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system.

filing / Aug 14, 2026 / receipt

b) Includes legal and patent expenses, information technology infrastructure and other costs, professional accounting, insurance, travel and entertainment and other third party services and expenses.

filing / May 8, 2026 / receipt

As discussed in Note 8 to our Condensed Consolidated Financial Statements, we have incurred significant contract termination costs as a result of our prior restructuring plans.

filing / May 8, 2026 / receipt

As a result of our prior restructuring plans, we are seeking to sublease all of leased facilities in San Francisco, California, including our laboratory and office space on Mission Bay Blvd.

filing / May 8, 2026 / receipt

South (the Mission Bay Facility) and our office space on Third St. (the Third. St. Facility), and we have current subleases for a portion of the Mission Bay Facility.

filing / May 8, 2026 / receipt

In connection with our prior restructuring plans, we have incurred significant contract termination costs. Because we continue to adjust the liability based on updates to our assumptions at each reporting date, we continue to recognize expense as our estimates change until settlement.

filing / May 8, 2026 / receipt

Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system.

filing / May 8, 2026 / receipt

executives
Gil M. Labrucherie Chief Operating Officer - receipt
John Nicholson Senior Vice President and Chief Operating Officer - receipt
familynone on file
upcoming
2026-11-05 earnings call scheduled webcast / ir
changes
2025-11-21 Chief Legal Officer, departed sec_8k
2023-06-23 Chief Financial Officer, departed sec_8k
2023-04-17 Chief Financial Officer, departed sec_8k
2022-07-01 Chief Financial Officer, departed sec_8k
2022-04-25 Senior Vice President and Chief Commercial Officer, departed sec_8k
2019-12-05 Senior Vice President and Chief Commercial Officer, appointed sec_8k
2019-10-01 Chief Operating Officer, appointed sec_8k
2016-06-02 Senior Vice President and Chief Operating Officer, appointed sec_8k
mcp_package_hint
steadybase-$